Table 3.
Inhibition of live SARS-CoV replication in Vero 76 cells.
| Compound | Virus strain | CPE inhibition |
Neutral red (NR) assay |
Virus yield reduction | ||||
|---|---|---|---|---|---|---|---|---|
| IC50a (μM) | CC50b (μM) | SIc | IC50a (μM) | CC50b (μM) | SIc | IC90d (μM) | ||
| K11777 | Urbani | <0.05 ± 0 | >105.6 ± 59.3 | >2112 | 0.52 ± 0.17 | >100.3 ± 64.2 | >192.9 | 0.35 ± 0.35 |
| Toronto-2 | <0.05 ± 0 | 85.2 ± 0 | >1704 | 0.35 ± 0.17 | 52.7 ± 7.8 | 150.6 | 1.04 ± 1.22 | |
| SMDC256159 | Urbani | 0.65 ± 0.81 | >109.2 ± 49.8 | >168 | <2.26 ± 3.56 | >91.6 ± 65.6 | >40.5 | 7.1 ± 7.6 |
| Toronto-2 | <0.48e | 85.6 | >178.3 | 0.65 | 61.4 | 94.5 | <0. 48 | |
| SMDC256160 | Urbani | <0.08 ± 0.05 | 50.6 ± 26.7 | >632.5 | <0.13 ± 0.03 | >81.8 ± 58.5 | >629.2 | 0.49 ± 0 |
| Toronto-2 | <0.05 | 27.6 | >552 | 0.32 | 30.8 | 96.3 | 12.2 | |
a
50% virus inhibitory concentration.
b
50% cell cytotoxic concentration of drug.
c
Selective index: SI = CC50/IC50.
d
90% virus inhibitory concentration.
e
No SDs were reported when n ⩽ 2.